Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | mBTCvax |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
mBTCvax is a personalized cancer vaccine comprising patient tumor-derived neoantigen peptides combined with poly-ICLC, which may induce a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary) |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C214983 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Durvalumab + mBTCvax + Tremelimumab | Durvalumab Tremelimumab mBTCvax | 0 | 1 |
| mBTCvax | mBTCvax | 0 | 0 |